Aridis Pharmaceuticals (ARDS) Competitors $0.0001 +0.00 (+∞) (As of 12/20/2024 02:47 PM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsFinancialsSEC FilingsTrends ARDS vs. NAVB, EVLO, SCPS, GNCAQ, GNCA, STAB, AMPE, CMRA, CALA, and EFTRShould you be buying Aridis Pharmaceuticals stock or one of its competitors? The main competitors of Aridis Pharmaceuticals include Navidea Biopharmaceuticals (NAVB), Evelo Biosciences (EVLO), Scopus BioPharma (SCPS), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Statera Biopharma (STAB), Ampio Pharmaceuticals (AMPE), Comera Life Sciences (CMRA), Calithera Biosciences (CALA), and eFFECTOR Therapeutics (EFTR). These companies are all part of the "pharmaceutical products" industry. Aridis Pharmaceuticals vs. Navidea Biopharmaceuticals Evelo Biosciences Scopus BioPharma Genocea Biosciences Genocea Biosciences Statera Biopharma Ampio Pharmaceuticals Comera Life Sciences Calithera Biosciences eFFECTOR Therapeutics Navidea Biopharmaceuticals (NYSE:NAVB) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking. Does the MarketBeat Community believe in NAVB or ARDS? Aridis Pharmaceuticals received 122 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 61.00% of users gave Aridis Pharmaceuticals an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformNavidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes68100.00% Aridis PharmaceuticalsOutperform Votes12261.00% Underperform Votes7839.00% Is NAVB or ARDS more profitable? Company Net Margins Return on Equity Return on Assets Navidea BiopharmaceuticalsN/A N/A N/A Aridis Pharmaceuticals N/A N/A N/A Do institutionals & insiders have more ownership in NAVB or ARDS? 0.0% of Navidea Biopharmaceuticals shares are held by institutional investors. Comparatively, 9.6% of Aridis Pharmaceuticals shares are held by institutional investors. 43.7% of Navidea Biopharmaceuticals shares are held by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Does the media refer more to NAVB or ARDS? In the previous week, Aridis Pharmaceuticals had 1 more articles in the media than Navidea Biopharmaceuticals. MarketBeat recorded 1 mentions for Aridis Pharmaceuticals and 0 mentions for Navidea Biopharmaceuticals. Navidea Biopharmaceuticals' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score. Company Overall Sentiment Navidea Biopharmaceuticals Neutral Aridis Pharmaceuticals Neutral Which has stronger earnings and valuation, NAVB or ARDS? Navidea Biopharmaceuticals has higher earnings, but lower revenue than Aridis Pharmaceuticals. Navidea Biopharmaceuticals is trading at a lower price-to-earnings ratio than Aridis Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioNavidea Biopharmaceuticals$8.13K1.23-$15.18M-$0.060.00Aridis Pharmaceuticals$3.09M0.00-$30.37M-$0.160.00 Which has more volatility & risk, NAVB or ARDS? Navidea Biopharmaceuticals has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. SummaryAridis Pharmaceuticals beats Navidea Biopharmaceuticals on 6 of the 11 factors compared between the two stocks. Ad Behind the MarketsWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this window of opportunity is closing fast.Click here for the ticker >>> Get Aridis Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ARDS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ARDS vs. The Competition Export to ExcelMetricAridis PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$5,000.00$6.57B$5.14B$9.08BDividend YieldN/A3.00%5.09%4.23%P/E Ratio0.0010.5990.0517.20Price / Sales0.00196.061,117.09117.04Price / CashN/A57.1643.1037.85Price / Book0.005.094.784.78Net Income-$30.37M$151.83M$120.31M$225.60M Aridis Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ARDSAridis PharmaceuticalsN/A$0.00+∞N/A-99.9%$5,000.00$3.09M0.0030News CoverageNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-99.8%$10,000.00$8,126.000.0010Analyst ForecastEVLOEvelo BiosciencesN/A$0.00+25.0%N/A-99.1%$9,000.00N/A0.00120SCPSScopus BioPharmaN/A$0.00-33.3%N/A-99.3%$8,000.00N/A0.009Gap UpGNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.64M0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070Analyst ForecastSTABStatera BiopharmaN/A$0.00flatN/A-75.0%$5,000.00$1.49M0.0020AMPEAmpio PharmaceuticalsN/A$0.00+420.0%N/A-99.9%$3,000.00N/A0.0020Analyst ForecastCMRAComera Life SciencesN/A$0.00flatN/AN/A$3,000.00$630,000.000.002CALACalithera BiosciencesN/A$0.00-92.1%N/A-99.7%$1,000.00$9.75M0.0060Analyst ForecastGap DownEFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+11,999,900.0%-100.0%$1,000.00$3.55M0.0010 Related Companies and Tools Related Companies NAVB Alternatives EVLO Alternatives SCPS Alternatives GNCAQ Alternatives GNCA Alternatives STAB Alternatives AMPE Alternatives CMRA Alternatives CALA Alternatives EFTR Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ARDS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredAI breakthrough about to upend industryEveryone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the m...Porter & Company | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aridis Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aridis Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
